ORGANON & CO (OGN) Stock News
NYSE:OGN - New York Stock Exchange, Inc. - US68622V1061 - Common Stock - Currency: USD
OGN Latest News, Press Relases and Analysis
High-Yield Healthcare: 3 Stocks With Strong Dividends
This article covers three healthcare stocks that offer dividend yields of at least 7% and dives deeper into the fundamentals to determine if they're good buys.
Organon (OGN) Shares Skyrocket, What You Need To Know
Shares of pharmaceutical company Organon (NYSE:OGN) jumped 12.5% in the morning session after the company reported fourth-quarter 2024 results that topped analysts' revenue and EPS expectations. While sales were flat year on year, strength in Established Brands helped offset declines in Biosimilars and Women's Health. However, the company's full-year revenue outlook came in lower than expected, reflecting headwinds from foreign exchange and the loss of exclusivity for Atozet (the second-largest product) in key markets. Overall, this quarter was decent, but not perfect.
Organon (NYSE:OGN) Exceeds Q4 Expectations But Full-Year Sales Guidance Misses Expectations Significantly
Pharmaceutical company Organon (NYSE:OGN) reported Q4 CY2024 results exceeding the market’s revenue expectations, but sales were flat year on year at $1.59 billion. On the other hand, the company’s full-year revenue guidance of $6.23 billion at the midpoint came in 3.2% below analysts’ estimates. Its non-GAAP profit of $0.90 per share was 3.9% above analysts’ consensus estimates.
Organon (NYSE:OGN) Exceeds Q4 Expectations But Full-Year Sales Guidance Misses Expectations Significantly
Pharmaceutical company Organon (NYSE:OGN) reported Q4 CY2024 results exceeding the market’s revenue expectations, but sales were flat year on year at $1.59 billion. On the other hand, the company’s full-year revenue guidance of $6.23 billion at the midpoint came in 3.2% below analysts’ estimates. Its non-GAAP profit of $0.90 per share was 3.9% above analysts’ consensus estimates.
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024
Organon (OGN) Q4 Earnings Report Preview: What To Look For
Pharmaceutical company Organon (NYSE:OGN) will be reporting earnings tomorrow before market hours. Here’s what investors should know.
Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025
Want $2,000 in Annual Dividends? Invest $11,000 in Each of These 3 Stocks.
Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference
Organon Reports Results for the Third Quarter Ended September 30, 2024
US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
The acquisition expands Organon’s dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S.
Mentions: ROIV
Want $300 in Dividends Every Month? Invest $20,000 in Each of These 3 Stocks
These dividend stocks all pay yields of around 6% and higher.
Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024
Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
Mentions: ROIV
Organon Stock Sees Relative Strength Rating Rise To 91
On Tuesday, Organon[ stock hit an key technical milestone, seeing its Relative Strength Rating jump to 91, up from 88 the day before.
Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold
On Tuesday, generic drug maker Organon stock had its Relative Strength (RS) Rating upgraded to 83, up from 78 a day earlier.
